Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...

Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

The tribunal held that the resolution plan was invalid because several valuable properties were omitted from the Information Memorandum. The ruling emphasises that all assets must be valued and ...

AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start ...

The last bit of momentum for Broadcom is the sector-wide momentum behind custom silicon. Industry reporting continues to point to Broadcom as the go-to partner for hyperscaler accelerators and AI ASIC ...

A new strain of mpox, previously called monkeypox, has been detected in a person in England, say UK health officials. The virus is a mix of two major types of the mpox virus, and was found in someone ...

Time is critical for patients this December. The American Red Cross urges donors to make an appointment to give blood or ...

Wesleyan Christian will look to defend its Sheetz Holiday Christmas Classic sweep later this month when the 15th edition of ...

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused ...

When and where is the game? Who is Glenvar playing? What are the historical implications? Get answers to those questions and ...